Current Neuro-Oncology

Volume 22 Number 17
15 September 2020

Home > Publications > Current Neuro-Oncology > Volume 22, Year 2020 > Number 17, 15 September

Awada G, Serruys D, Schwarze JK, Van De Voorde L, Duerinck J, Neyns B.
Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1.
Case Rep Oncol. 2020 Sep 1, 2020;13(2):1031-1036∟. doi: 10.1159/000509773∟. PMID: 33082744∟. Case report. ˍ

Vloka C, Waman E.
Look beyond the retinopathy: The incidental finding of a brain tumour.
J Telemed Telecare. 2020 Sep 1, 2022;28(3):230-232∟. doi: 10.1177/1357633X20955123∟. PMID: 32873139∟. Case report. ˍ

Palpan Flores A, Vivancos Sanchez C, Roda JM, Cerdán S, Barrios AJ, Utrilla C, Royo A, Gandía González ML.
Assessment of Pre-operative Measurements of Tumor Size by MRI Methods as Survival Predictors in Wild Type IDH Glioblastoma.
Front Oncol. 2020 Sep 2, 2020;10:1662∟. doi: 10.3389/fonc.2020.01662∟. PMID: 32984040∟. Observational study. ˍ

Kotecha R, Hall MD.
Impact of Radiotherapy Dosimetric Parameters on Neurocognitive Function in Brain Tumor Patients.
Neuro Oncol. 2020 Sep 2, 2020;22(11):1559-1561∟. doi: 10.1093/neuonc/noaa208∟. PMID: 32875338∟. Comment. ˍ
Refers to: Goda JS, et al., Hippocampal radiotherapy dose-constraints for predicting long-term neurocognitive outcomes: Mature data from a prospective trial in young patients with brain tumors.
Neuro Oncol. 2020 Mar 30, 2020;22(11):1677-1685∟. doi: 10.1093/neuonc/noaa076∟. PMID: 32227185∟. Observational study. ˍ

Azzollini J, Schiavello E, Buttarelli FR, Clerici CA, Tizzoni L, Vecchi G, Capra F, Pisati F, Biassoni V, Runza L, Carrabba G, Giangaspero F, Massimino M, Pensotti V, Manoukian S.
Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma.
Cancers (Basel). 2020 Sep 3, 2020;12(9):E2503∟. doi: 10.3390/cancers12092503∟. PMID: 32899294∟. Case report. ˍ

Mullarkey MP, Nehme G, Mohiuddin S, Ballester LY, Bhattacharjee MB, Trivedi D, Shah MN, Fuller GN, Zaky W, Sandberg DI.
Posttreatment Maturation of Medulloblastoma into Gangliocytoma: Report of 2 Cases.
Pediatr Neurosurg. 2020 Sep 3, 2020;55(4):222-231∟. doi: 10.1159/000509520∟. PMID: 32882694∟. Case report. ˍ

Nikolova E, Dimova P, Minkin K, Todorov T, Mitev V, Todorova A.
Human cytomegalovirus DNA detection in a recurrent glioblastoma multiforme tumour, but not in whole blood: a case report and discussion about the HCMV latency and therapy perspectives.
J Neurovirol. 2020 Sep 3, 2020;26(6):984-987∟. doi: 10.1007/s13365-020-00901-9∟. PMID: 32880872∟. Case report. ˍ

Rahimi Koshkaki H, Minasi S, Ugolini A, Trevisi G, Napoletano C, Zizzari IG, Gessi M, Giangaspero F, Mangiola A, Nuti M, Buttarelli FR, Rughetti A.
Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma.
J Pers Med. 2020 Sep 3, 2020;10(3):E112∟. doi: 10.3390/jpm10030112∟. PMID: 32899203∟. Case report. ˍ

Zhu S, Lin F, Chen Z, Jiang X, Zhang J, Yang Q, Chen Y, Wang J.
Identification of a Twelve-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival for Medulloblastoma.
Front Genet. 2020 Sep 3, 2020;11:563882∟. doi: 10.3389/fgene.2020.563882∟. PMID: 33101383∟. Observational study. ˍ

Chen C, Zuo W, Yang P, Zhang Y.
Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report.
J Int Med Res. 2020 Sep 4, 2020;48(9):300060520951395∟. doi: 10.1177/0300060520951395∟. PMID: 32883128∟. Case report. ˍ

Gabrovsky N, Laleva M, Poptodorov G, Velinov N, Kamenova M, Kaneva R, Gabrovsky S.
Impact of surgical treatment on the performance status of patients with high-grade gliomas.
Neurol Res. 2020 Sep 5, 2020;42(12):1074-1079∟. doi: 10.1080/01616412.2020.1802147∟. PMID: 32892718∟. Observational study. ˍ

Guo D, Qu Y, Yang Y, Yang ZJ.
Medulloblastoma cells resemble neuronal progenitors in their differentiation.
Mol Cell Oncol. 2020 Sep 5, 2020;7(6):1810514∟. doi: 10.1080/23723556.2020.1810514∟. PMID: 33235914∟. Laboratory investigation. ˍ

Xu J, Liu F, Li Y, Shen L.
A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
Cell Mol Neurobiol. 2020 Sep 7, 2022 Apr;42(3):709-722∟. doi: 10.1007/s10571-020-00959-3∟. PMID: 32894375∟. Observational study. ˍ

Kawada T.
Factors influencing survival in patients with glioblastoma: A risk assessment.
J Formos Med Assoc. 2020 Sep 8, 2021 Feb;120(2):911∟. doi: 10.1016/j.jfma.2020.08.044∟. PMID: 32917482∟. Comment. ˍ
Refers to: Shieh LT, et al., Clinical implications of multiple glioblastomas: An analysis of prognostic factors and survival to distinguish from their single counterparts.
J Formos Med Assoc. 2019 Sep 10, 2020;119(3):728-734∟. doi: 10.1016/j.jfma.2019.08.024∟. PMID: 31515159∟. Observational study. ˍ

Portnow J, Badie B, Suzette Blanchard M, Kilpatrick J, Tirughana R, Metz M, Mi S, Tran V, Ressler J, D'Apuzzo M, Aboody KS, Synold TW.
Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients.
Cancer Gene Ther. 2020 Sep 8, 2021;28(3-4):294-306∟. doi: 10.1038/s41417-020-00219-y∟. PMID: 32895489∟. Interventional study. ˍ

Singh GK, Menon N, Jadhav MM, Walavalkar R, DSouza H, Roy S, Das S, Srinivas S, Vallathol DH, Patil VM.
Thromboembolic events in brain tumour patients on bevacizumab.
Acta Oncol. 2020 Sep 8, 2020;59(12):1543-1546∟. doi: 10.1080/0284186X.2020.1815834∟. PMID: 32897111∟. Letter to the editor. ˍ

Hollingworth MA, Zacharoulis S.
Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore.
J Neurooncol. 2020 Sep 9, 2020;149(2):263-272∟. doi: 10.1007/s11060-020-03594-6∟. PMID: 32902768∟. Observational study. ˍ

Tran S, Lim PS, Bojaxhiu B, Teske C, Baust K, Zepter S, Kliebsch U, Timmermann B, Calaminus G, Weber DC.
Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy.
Pediatr Blood Cancer. 2020 Sep 9, 2020;67(12):e28465∟. doi: 10.1002/pbc.28465∟. PMID: 32902137∟. Observational study. ˍ

Su X, Sun H, Chen N, Roberts N, Yang X, Wang W, Li J, Huang X, Gong Q, Yue Q.
A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.
Clin Radiol. 2020 Sep 10, 2020;75(12):963.e7-963.e15∟. doi: 10.1016/j.crad.2020.07.036∟. PMID: 32921406∟. Observational study. ˍ

Faustino AC, Viani GA, Hamamura AC.
Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Clinics (Sao Paulo). 2020 Sep 11, 2020;75:e1553∟. doi: 10.6061/clinics/2020/e1553∟. PMID: 32935821∟. Observational study. ˍ

Gao M, Huang S, Pan X, Liao X, Yang R, Liu J.
Machine Learning-Based Radiomics Predicting Tumor Grades and Expression of Multiple Pathologic Biomarkers in Gliomas.
Front Oncol. 2020 Sep 11, 2020;10:1676∟. doi: 10.3389/fonc.2020.01676∟. PMID: 33014836∟. Observational study. ˍ

Regnery S, Behl NGR, Platt T, Weinfurtner N, Windisch P, Deike-Hofmann K, Sahm F, Bendszus M, Debus J, Ladd ME, Schlemmer HP, Rieken S, Adeberg S, Paech D.
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
Neuroimage Clin. 2020 Sep 12, 2020;28:102427∟. doi: 10.1016/j.nicl.2020.102427∟. PMID: 33002860∟. Observational study. ˍ

Miele E, Po A, Mastronuzzi A, Carai A, Besharat ZM, Pediconi N, Abballe L, Catanzaro G, Sabato C, De Smaele E, Canettieri G, Di Marcotullio L, Vacca A, Mai A, Levrero M, Pfister SM, Kool M, Giangaspero F, Locatelli F, Ferretti E.
Downregulation of miR-326 and its host gene β-arrestin1 induces pro survival activity of E2F1 and promotes medulloblastoma growth.
Mol Oncol. 2020 Sep 13, 2021;15(2):523-542∟. doi: 10.1002/1878-0261.12800∟. PMID: 32920979∟. Laboratory investigation. ˍ

Miller JJ, Cahill DP.
MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma.
Neuro Oncol. 2020 Sep 14, 2020 Nov 26;22(11):1553-1554∟. doi: 10.1093/neuonc/noaa212∟. PMID: 32927482∟. Comment. ˍ
Refers to: Mathur R, et al.,MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020 Mar 13, 2020;22(11):1580-1590∟. doi: 10.1093/neuonc/noaa059∟. PMID: 32166314∟. Laboratory investigation. ˍ

Chen C, Zheng A, Ou X, Wang J, Ma X.
Comparison of Radiomics-Based Machine-Learning Classifiers in Diagnosis of Glioblastoma From Primary Central Nervous System Lymphoma.
Front Oncol. 2020 Sep 15, 2020;10:1151∟. doi: 10.3389/fonc.2020.01151∟. PMID: 33042784∟. Observational study. ˍ

Dudley HJ, Ren ZJ, Bortz DM.
Brain tumor classification in MRI image using convolutional neural network.
Math Biosci Eng. 2020 Sep 15, 2020;17(5):6203-6216∟. doi: 10.3934/mbe.2020328∟. PMID: 33120595∟. Observational study. ˍ

Korshoej AR, Lukacova S, Lassen-Ramshad Y, Rahbek C, Severinsen KE, Guldberg TL, Mikic N, Jensen MH, Cortnum SOS, von Oettingen G, Sørensen JCH.
OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma.
Neurooncol Adv. 2020 Sep 15, 2020;2(1):vdaa121∟ doi: 10.1093/noajnl/vdaa121∟. PMID: 33215088∟. Interventional study. ˍ